ClinicalTrials.gg
RecruitingNCT07586891Updated May 14, 2026

Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma

An interventional study of Low Branched-Chain Amino Acid Diet in Melanoma (Skin Cancer), sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jul 2024, registered Nov 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
69th of 189
80 · median 50
Started
2024
with 11 others
No phase
8 of 203
4 open now
Primary completion
2026-12
later than 38 of 94 live
Registered
173rd of 203
by date
Lead sponsor
5 of 203
Xijing Hospital

Among the 203 studies in Melanoma with a site in China, this one is the 69th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 8 with no phase, reaches primary completion later than 38 of the 94 other live ones, and was the 173rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

  1. Primary Objective:

    To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as neoadjuvant therapy in patients with stage III melanoma, by documenting the incidence of all adverse events (AEs) and serious adverse events (SAEs), and analyzing changes from baseline in physical examinations, vital signs, and laboratory test results.

  2. Secondary Objectives:

    To assess the pathological response rates (including pCR, near-pCR, pPR, and pNR) of the combination therapy in stage III melanoma; to evaluate the objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and the immune-related RECIST (irRECIST) criteria; and to estimate event-free survival (EFS) and overall survival (OS) through long-term follow-up.

  3. Exploratory Objectives:

To investigate the quality of life (QoL) in patients receiving the low BCAA diet combined with anti-PD-1 therapy; and to identify predictive biomarkers for treatment outcome differences, such as immune-related gene signatures (e.g., PD-L1 expression) and driver gene mutations in somatic variants.

03

Conditions studied

  • Melanoma (Skin Cancer)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histopathologically or confirmed Stage III malignant melanoma. Stage III is defined as the presence of at least one clinically accessible lymph node or in-transit metastasis. Patients with mucosal or ocular melanoma are excluded; those with melanoma of unknown primary are also excluded.
  • No prior radiotherapy or systemic chemotherapy. No treatment with , anti-PD-L1, anti-PD-L2 monoclonal antibodies, anti-CTLA-4 monoclonal antibody, interferon (IFN), or targeted agents within the last month.
  • ≥ 6 months.
  • At least one as defined by version 1.1.
  • Patients must have provided written to participate voluntarily in this trial and must be between 18 and 75 years of age on the day of signing the consent form.
  • (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
  • Adequate organ function as assessed by the following laboratory values (within 4 weeks prior to the start of study drug treatment):

    1. (ANC) ≥ 1.5 × 10⁹/L
    2. ≥ 100 × 10⁹/L
    3. ≥ 90 g/L (no transfusion within 14 days prior to enrollment)
    4. Serum creatinine ≤ 1.5 × (ULN)
    5. Serum total ≤ 1.5 × ULN
    6. (SGOT) and ALT (SGPT) ≤ 2.5 × ULN or ≤ 5 × ULN (for patients with liver metastases)
    7. (PT)/International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless the patient is on anticoagulant therapy, in which case PT or aPTT must be within the therapeutic range intended for the anticoagulant).
  • For women of , a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of the study drug.
  • Female patients of childbearing potential who enroll in the study must be willing to use adequate for up to 12 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • The patient is currently participating, or has participated in a clinical trial of an drug or medical device within 4 weeks prior to the first dose of the study drug.
  • The patient has received any anti-tumor therapy within the past month, including but not limited to chemotherapy, radiotherapy, immunotherapy (such as , anti-PD-L1, or anti-CTLA-4 antibodies, or any other antibody targeting T-cell co-regulatory pathways), etc.
  • The patient has received systemic therapy (>10 mg/kg prednisone or equivalent) within two weeks prior to the first dose, or any other form of therapy.
  • The patient has a known history of hematologic , primary brain tumors, sarcoma, or other primary solid tumors, unless the patient has been cured and has had no evidence of recurrence for 5 years. Exceptions include cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  • The patient has known central nervous system (CNS) and/or carcinomatous meningitis.
  • The patient has a history of severe reaction to another monoclonal antibody (mAb) therapy.
  • The patient has an active disease that has required systemic treatment in the past 2 years (e.g., with corticosteroids or immunosuppressive drugs). Replacement therapies (such as thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) are not considered systemic treatments and are allowed. Exceptions include patients with vitiligo, type I diabetes mellitus, or childhood asthma/atopy.
  • Any other severe, uncontrolled co-morbid condition that may compromise protocol compliance or interfere with the interpretation of results, including metabolic diseases, active opportunistic or advanced (severe) infections, cardiovascular disease (e.g., Class III or IV heart failure as defined by the classification, second-degree or greater heart block, myocardial infarction within the past 6 months, unstable arrhythmias or unstable angina, cerebral infarction within 3 months), or pulmonary disease (interstitial lung disease, obstructive pulmonary disease, history of symptomatic bronchospasm). Also included are positivity; positivity; or HBcAb positivity with detectable HBV DNA (quantitation limit: 500 IU/mL); or a known history of tuberculosis.
  • The patient has received a within 4 weeks prior to the first dose. The patient has received hematopoietic growth factors (e.g., colony-stimulating factors, erythropoietin) within 2 weeks prior to treatment initiation. The patient has undergone major surgical procedures (excluding diagnostic surgery) within 2 weeks prior to treatment initiation.
  • The patient has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
  • The patient is pregnant or breastfeeding, or plans to conceive or father children during the study period.
  • Any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with the interpretation of study results.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
80 participants (estimated)

Study arms

  • No intervention
    Control Group

    Standard diet,anti-PD-1 and other essential drugs

  • Experimental
    Experimental Group

    Low BCAA diet, anti-PD-1 and other essential drugs

    Dietary Supplement: Low Branched-Chain Amino Acid Diet

Interventions

  • Dietary supplementLow Branched-Chain Amino Acid Diet

    The experimental group receives a low branched-chain amino acid diet

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure

    Systolic blood pressure

    Time frame: through study completion, an average of 3 months

  2. respiratory rate

    respiratory rate

    Time frame: through study completion, an average of 3 months

  3. body temperature

    body temperature

    Time frame: through study completion, an average of 3 months

  4. heart rate

    heart rate

    Time frame: through study completion, an average of 3 months

  5. Left ventricular ejection fraction (LVEF)

    LVEF assessed by echocardiography.

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  6. Hemoglobin concentration

    Hemoglobin concentration assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  7. White blood cell count

    White blood cell count assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  8. Platelet count

    Platelet count assessed by complete blood count

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  9. Alanine aminotransferase (ALT) level

    ALT level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  10. Aspartate aminotransferase (AST) level

    AST level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  11. Creatinine level

    Creatinine level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  12. Blood glucose level

    Blood glucose level measured from clinical biochemistry panel (fasting or as specified in protocol)

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  13. Lactate dehydrogenase (LDH) level

    LDH level measured from clinical biochemistry panel

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  14. Triiodothyronine (T3) level

    T3 level measured from blood sample.

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  15. Thyroid-stimulating hormone (TSH) level

    TSH level measured from blood sample.

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  16. Left ventricular end-diastolic diameter (LVEDD)

    LVEDD assessed by echocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  17. Cardiac output

    Cardiac output estimated by echocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  18. PR interval

    PR interval assessed by 12-lead electrocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

  19. QRS duration

    QRS duration assessed by 12-lead electrocardiography

    Time frame: Baseline and every 8 weeks through study completion (up to 3 months)

Secondary outcomes

  1. Lymph node target lesion short-axis diameter

    Short-axis diameter of target lesions in lymph nodes, assessed by imaging (e.g., ultrasonography, CT, or MRI per schedule of assessments)

    Time frame: Baseline and every 3 weeks through study completion (up to 3 months)

  2. Percentage of residual viable tumor cells in lymph nodes

    Proportion of viable tumor cells in lymph node tissue assessed by histopathological analysis.

    Time frame: Perioperative (after 3 months of treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5. PubMed 21639810 ↗
  • Biswas D, Duffley L, Pulinilkunnil T. Role of branched-chain amino acid-catabolizing enzymes in intertissue signaling, metabolic remodeling, and energy homeostasis. FASEB J. 2019 Aug;33(8):8711-8731. doi: 10.1096/fj.201802842RR. Epub 2019 May 14. PubMed 31084571 ↗
  • Tedesco L, Corsetti G, Ruocco C, Ragni M, Rossi F, Carruba MO, Valerio A, Nisoli E. A specific amino acid formula prevents alcoholic liver disease in rodents. Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G566-G582. doi: 10.1152/ajpgi.00231.2017. Epub 2018 Jan 25. PubMed 29368944 ↗
  • Saha AK, Xu XJ, Lawson E, Deoliveira R, Brandon AE, Kraegen EW, Ruderman NB. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes. 2010 Oct;59(10):2426-34. doi: 10.2337/db09-1870. Epub 2010 Aug 3. PubMed 20682696 ↗
  • Saxton RA, Knockenhauer KE, Wolfson RL, Chantranupong L, Pacold ME, Wang T, Schwartz TU, Sabatini DM. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science. 2016 Jan 1;351(6268):53-8. doi: 10.1126/science.aad2087. Epub 2015 Nov 19. PubMed 26586190 ↗
  • Peng H, Wang Y, Luo W. Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene. 2020 Oct;39(44):6747-6756. doi: 10.1038/s41388-020-01480-z. Epub 2020 Sep 25. PubMed 32978521 ↗
  • Bigger CH, Braymer HD. Neurospora crassa invertase. A study of amino acids at the active center. Biochim Biophys Acta. 1975 Aug 26;397(2):418-27. doi: 10.1016/0005-2744(75)90131-x. PubMed 239750 ↗
  • Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017 Apr 18;10(1):93. doi: 10.1186/s13045-017-0463-6. PubMed 28420416 ↗
  • Auslander N, Yizhak K, Weinstock A, Budhu A, Tang W, Wang XW, Ambs S, Ruppin E. A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer. Sci Rep. 2016 Jul 13;6:29662. doi: 10.1038/srep29662. PubMed 27406679 ↗
  • Li JT, Li KY, Su Y, Shen Y, Lei MZ, Zhang F, Yin M, Chen ZJ, Wen WY, Hu WG, Su D, Qu J, Lei QY. Diet high in branched-chain amino acid promotes PDAC development by USP1-mediated BCAT2 stabilization. Natl Sci Rev. 2021 Nov 26;9(5):nwab212. doi: 10.1093/nsr/nwab212. eCollection 2022 May. PubMed 35663242 ↗
  • Wang Z, Lu Z, Lin S, Xia J, Zhong Z, Xie Z, Xing Y, Qie J, Jiao M, Li Y, Wen H, Zhao P, Zhang D, Zhou P, Qian J, Luo F, Wang L, Yu H, Liu J, Gu J, Liu R, Chu Y. Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion. Immunity. 2022 Jun 14;55(6):1067-1081.e8. doi: 10.1016/j.immuni.2022.04.017. Epub 2022 Jun 3. PubMed 35659337 ↗
  • Silva LS, Poschet G, Nonnenmacher Y, Becker HM, Sapcariu S, Gaupel AC, Schlotter M, Wu Y, Kneisel N, Seiffert M, Hell R, Hiller K, Lichter P, Radlwimmer B. Branched-chain ketoacids secreted by glioblastoma cells via MCT1 modulate macrophage phenotype. EMBO Rep. 2017 Dec;18(12):2172-2185. doi: 10.15252/embr.201744154. Epub 2017 Oct 24. PubMed 29066459 ↗
  • Ikeda K, Kinoshita M, Kayama H, Nagamori S, Kongpracha P, Umemoto E, Okumura R, Kurakawa T, Murakami M, Mikami N, Shintani Y, Ueno S, Andou A, Ito M, Tsumura H, Yasutomo K, Ozono K, Takashima S, Sakaguchi S, Kanai Y, Takeda K. Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells. Cell Rep. 2017 Nov 14;21(7):1824-1838. doi: 10.1016/j.celrep.2017.10.082. PubMed 29141216 ↗
  • Chirmule NB, Chaturvedi RM, Deo MG. Immunogenic "subunit" of the ICRC antileprosy vaccine. Int J Lepr Other Mycobact Dis. 1988 Mar;56(1):27-35. PubMed 3131465 ↗
  • Collard WM. Diagnosing earache in infants and small children. S Afr Med J. 1985 Dec 21;68(13):916. No abstract available. PubMed 4081922 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 29 months is below that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
May 14, 2026
StartActual
Jul 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586891
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jul 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 14, 2026

Study contacts

Weinan Guo
Contact
guown@fmmu.edu.cn
+ 86-29-84775406

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion